Peter Grell MD路 @GrellMd 路 X路路 14 hours agoScore70
Body
Standing ovation at #ESMO26! 馃憦
Practice-changing Phase 3 results from DeLLphi-305 (LBA3) for maintenance tarlatamab + durvalumab in 1L ES-SCLC: mOS: 21.1 vs 12.7 mo (HR 0.42; p < 0.001)
A new standard of care with BiTE + ICI馃挜
22 views 路 0 likes 路 0 reposts 路 0 replies
Conference abstracts
LBA3matched by Presidential Symposium I
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: Peter Grell MD 路 x.com